Company
NovaResp
Adherence equals traction in the CPAP market
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- MANUFACTURER, DMEs
- novaresp.ai (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 17 September 2026
About
cMAP® is a platform software that uses artificial intelligence and machine learning during PAP therapy to predict and prevent episodes of apnea before they occur. As a result, personalized therapy can be delivered via PAP machines at lower, more comfortable air pressure levels.
Funding snapshot
- Total raised
- $5MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Seed extension, $3M2024-05-14
Funding rounds
- Seed extension
- $3M2024-05-14, Company stated
- Seed
- $2M2023-01-26, Company stated
Products
- Other
- cMAP®
Loading relationship preview